EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Follow-up in non-muscle invasive bladder cancer: facts and future

J Alfred Witjes

World Journal of Urology · 2021-11 · 39 (11) · 4047-4053

DOI: 10.1007/s00345-020-03569-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift World Journal of Urology, online erschienen am 26.12.2020. Verfasst von J Alfred Witjes. Beteiligte Einrichtung: Department of Urology, University Medical Center Nijmegen, Radboudumc (610), P. O. Box 9101, 6500 HB, Nijmegen, The Netherlands. Fred.witjes@radboudu…. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with non-muscle invasive bladder cancer (NMIBC) have high recurrence and progression rates in spite of tumor resection and adjuvant instillation therapy. To detect recurrences and progression, these patients remain under frequent follow-up. Follow-up, however, is not well defined. Frequency and duration of follow recommendations are based on low levels of evidence, which is illustrated by clear differences in these recommendations per guideline, even when specified per risk group. Additionally, follow-up is recommended with cystoscopy and cytology in selected patients, which both have clear limitations. Fact is that follow-up in NMIBC is too frequent, with low levels of evidence and suboptimal tools, and it is patient unfriendly and costly. Improved cystoscopy techniques are unproven or impractical in the outpatient follow-up setting. Urinary markers have been around for decades, but never widely used in clinical practice. New (epi)genetic markers, however, could play a significant role in future follow-up of NMIBC. They have been shown to have very high negative predictive values for recurrences in follow-up of NMIBC, especially high-grade recurrences. Several studies suggested that these markers could be used to adapt follow-up cystoscopy frequency. What still needs study and confirmation is the cost-effectiveness of the use of these markers, which is highly dependent on health care costs per country and marker price. In all, however, implementation of these new urinary markers after confirmation of current results might significantly reduce patient burden and health care costs in the near future without reducing quality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorCystoscopyFollow-Up StudiesHumansNeoplasm InvasivenessPrognosisUrinary Bladder Neoplasms

Stichwörter der Autor:innen

CostsFollow-upNon-muscle invasive bladder cancerRisk groupsUrinary markers

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Urology, University Medical Center Nijmegen, Radboudumc (610), P. O. Box 9101, 6500 HB, Nijmegen, The Netherlands. Fred.witjes@radboudumc.nl.

Zitieren

APA

Witjes, J. A. (2021). Follow-up in non-muscle invasive bladder cancer: facts and future. World Journal of Urology, 39(11), 4047-4053. https://doi.org/10.1007/s00345-020-03569-2

Vancouver

Witjes JA. Follow-up in non-muscle invasive bladder cancer: facts and future. World Journal of Urology. 2021;39(11):4047-4053. doi:10.1007/s00345-020-03569-2

BibTeX
@article{Witjes2021,
  author = {Witjes, J Alfred},
  title = {Follow-up in non-muscle invasive bladder cancer: facts and future},
  journal = {World Journal of Urology},
  year = {2021},
  volume = {39},
  number = {11},
  pages = {4047--4053},
  doi = {10.1007/s00345-020-03569-2}
}
Kostenlos starten →